Monte Rosa Therapeutics, Inc. Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment
Monte Rosa Therapeutics, Inc. (GLUE) reported Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Compensation Related Costs › Retirement Benefits › Defined Benefit Plan › Defined Benefit Plan, Roll Forwards
us-gaap:DefinedBenefitPlanPlanAmendments · last filed 2026-03-17
- Monte Rosa Therapeutics, Inc. defined benefit plan, benefit obligation, increase (decrease) for plan amendment for fiscal 2025 was $0.00.
- Monte Rosa Therapeutics, Inc. defined benefit plan, benefit obligation, increase (decrease) for plan amendment for fiscal 2024 was -$9.00K.
- Monte Rosa Therapeutics, Inc. defined benefit plan, benefit obligation, increase (decrease) for plan amendment for fiscal 2023 was -$1.46M.
- Monte Rosa Therapeutics, Inc. defined benefit plan, benefit obligation, increase (decrease) for plan amendment for fiscal 2022 was -$67.00K.
| Period end | Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment 12 month | Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment 12 month as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-17 | |
| 2024-12-31 | -$9.00K 10-K · filed 2026-03-17 | |
| 2023-12-31 | -$1.46M 10-K · filed 2025-03-20 | |
| 2022-12-31 | -$67.00K 10-K · filed 2024-03-14 | $67.00K 10-K · filed 2023-03-16 |
| 2021-12-31 | -$42.00K 10-K · filed 2023-03-16 | |
| 2020-12-31 | $0.00 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |